Vemurafenib + Sorafenib for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

Overseen byErkut Borazanci, MD, MS

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: HonorHealth Research Institute

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing two types of cancer-fighting pills, Vemurafenib and Sorafenib, in patients with a specific type of pancreatic cancer. These patients have not improved with standard treatments. The pills work by blocking signals that help the cancer cells grow. Sorafenib is an oral multiple kinase inhibitor that has been approved for the treatment of advanced liver and kidney cancers.

Research Team

Erkut Borazanci, MD, MS

Principal Investigator

HonorHealth Research Institute

Eligibility Criteria

This trial is for adults over 18 with KRAS mutated pancreatic cancer that has spread and worsened after at least two prior treatments. Participants must be able to take oral meds, have good organ function, not be pregnant or breastfeeding, agree to use contraception, and have no major health issues that could interfere with the study.

Inclusion Criteria

I know my cancer's KRAS and BRAF mutation status or have a sample for testing.

My organs are functioning well.

I am 18 years old or older.

See 9 more

Exclusion Criteria

I haven't had cancer treatment in the last 2 weeks and have recovered from past treatment side effects.

I have not had serious lung bleeding or any severe bleeding in the last month.

I have stable brain metastases and haven't used steroids in the last 7 days.

See 21 more

Treatment Details

Interventions

Sorafenib (Kinase Inhibitor)
Vemurafenib (Kinase Inhibitor)

Trial OverviewThe trial tests Vemurafenib and Sorafenib's effectiveness in treating advanced pancreatic cancer with a specific mutation. These are oral chemotherapy drugs given to those who haven't responded well to standard treatments.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Vemurafenib in Combination with SorafenibExperimental Treatment2 Interventions

Sorafenib is already approved in Canada, Japan for the following indications: